Leqembi – Talk Bio

Eisai Expands Leqembi Subcutaneous Label, Accelerates Early U.S. Launch Progress for Alzheimer’s Disease

1 month ago talkbio0Tagged Alzheimer 's disease, at-home injection, dosing, Eisai, expansion, Labels (device), Leqembi, Maintenance, sBLA, starting dose, status - In progress, Subcutaneous Autoinjector, supplemental biologics, United States Food and Drug Administration

Eisai; Leqembi; subcutaneous autoinjector; label expansion; Supplemental Biologics License Application (sBLA); FDA; maintenance dosing; starting dose; early Alzheimer’s disease; at-home injection; launch progress

Eisai Secures FDA Approval for Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s Patients

3 months ago talkbio0Tagged Alzheimer 's disease, Approved, at-home, AutoInjector, Biogen, dosing, Eisai, Lecanemab, Leqembi, Maintenance, Subcutaneous Injections, United States Food and Drug Administration

Eisai; Leqembi; lecanemab; FDA approval; autoinjector; subcutaneous injection; maintenance dosing; Alzheimer’s disease; at-home treatment; Biogen

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

4 months ago talkbio0Tagged Antibodies, BioArctic, Blood - brain barrier anatomy, BrainTransporter platform, Leqembi, milestone payments, Nerve Degeneration, Novartis, Partnership, royalties

Novartis; BioArctic; BrainTransporter platform; blood-brain barrier; neurodegeneration; Leqembi; partnership; antibody; milestone payments; royalties

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

7 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Biogen says Leqembi sales are improving slowly following lackluster launch

7 months ago talkbio0Tagged Biogen, Eisai, Growth, Improving (qualifier value), Leqembi, Sales - occupational activity, United States Food and Drug Administration

Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

8 months ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth

9 months ago talkbio0Tagged Alzheimer 's disease, Biogen, Eisai, Leqembi, Projections and Predictions, Sales - occupational activity

Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection

Australia Rejects Eisai’s Alzheimer’s Drug Leqembi

9 months ago9 months ago talkbio0Tagged Alzheimer 's disease, Australia, drug rejection, Eisai, Leqembi, Transposition of Great Vessels

Leqembi, Eisai, Alzheimer’s disease, Australia, TGA, drug rejection

Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi

9 months ago talkbio0Tagged Alzheimer 's disease, Australia, Decision, Eisai, Lecanemab, Leqembi, Presenile dementia

Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia

Eisai Cuts 121 US Jobs in Strategic Restructuring

9 months ago talkbio0Tagged Alzheimer 's disease, Drug Industry, Eisai, Leqembi, restructuring, Surgical aspects, U.S.

Eisai, layoffs, restructuring, US operations, pharmaceutical industry, Leqembi, Alzheimer’s disease